At this stage, extensive research should to be done to test the toxicity of a p16Ink4a -driven suicide gene therapy strategy against additional tumor types of both murine and human origin, and further characterization of the portion of the p16Ink4a promoter activated in p16Ink4a -overexpressing cancer cells. The gene discussed is CDKN2A; the disease is cancer.